Healthcare Services

Neurogenetic Testing Market Trends And Growth Outlook Across The 2026–2030 Forecast Period

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, How Much Growth In Market Size Is Expected For The Neurogenetic Testing Market?

The neurogenetic testing market has experienced rapid expansion in recent years. It is projected to increase from $0.7 billion in 2025 to $0.79 billion in 2026, with a compound annual growth rate (CAGR) of 13.5%. Historically, this growth can be attributed to the early adoption of PCR-based genetic testing, a rising prevalence of inherited neurological disorders, enhanced utilization of microarray platforms, the development of advanced early diagnostic techniques, and the initial integration of genetic screening into clinical workflows.

The neurogenetic testing market is poised for significant expansion in the coming years. Projections indicate it will reach $1.24 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.9%. This anticipated growth during the forecast period is fueled by several factors, including an escalating demand for next-generation sequencing, the expanding scope of clinical exome sequencing, increased capital allocation towards genetic research, the creation of sophisticated molecular diagnostic instruments, and the wider acceptance of tailored neurological treatment strategies. Key trends expected over the forecast horizon encompass a greater embrace of whole-exome sequencing technologies, a surge in the application of PCR-based neurological genetic assays, wider deployment of microarray analysis, an increase in screening for uncommon neurological genetic conditions, and a heightened need for prompt diagnosis and foresightful testing.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16131&type=smp

Which Strategic Drivers Are Supporting The Neurogenetic Testing Market Development?

An increasing incidence of neurological conditions is anticipated to fuel the expansion of the neurogenetic testing market. These conditions encompass any ailments impacting the nervous system, including the brain, spinal cord, and associated nerves. Their widespread occurrence stems from factors such as genetic susceptibility, infections, physical trauma, exposure to toxins, autoimmune reactions, and degenerative processes. Neurogenetic testing plays a crucial role in improving the diagnosis, therapeutic approaches, and overall management of neurological disorders. It achieves this by providing customized data on genetic risk factors, informing treatment strategies, and enabling individuals and their families to make well-informed healthcare decisions, ultimately leading to better patient care and results. As an illustration of this escalating global health concern, the World Federation of Neurology, a UK-based charitable organization, reported in October 2023 that neurological disorders have become the second-leading cause of death and the primary source of disability globally. In 2023, over 40 percent of the world’s population was affected, with projections indicating a near doubling in the number of individuals afflicted by brain disease by 2050. Consequently, the growing frequency of neurological disorders is expected to stimulate the expansion of the neurogenetic testing market.

What Segment Types Are Included In The Neurogenetic Testing Market Analysis?

The neurogenetic testing market covered in this report is segmented –

1) By Type: Microarray Analysis, Whole-Exome Sequencing (WES), Multiplex Ligation Dependent Probe Amplification (MLPA), Polymerase Chain Reaction (PCR) Tests, Other Types

2) By Disease: Rare Genetic Disorder, Huntington’s Disease, Fragile X Syndrome, Other Diseases

3) By End-Users: Hospitals, Specialty Clinics, Research Institutes, Diagnostics Laboratories

Subsegments:

1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray, Single Nucleotide Polymorphism (SNP) Microarray, Gene Expression Microarray

2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing, Clinical Exome Sequencing, Research-Grade Exome Sequencing

3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation, MLPA For Methylation Analysis, MLPA For Specific Disease Detection

4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR (dPCR)

5) By Other Types: Next-Generation Sequencing (NGS), Southern Blotting, Fluorescence In Situ Hybridization (FISH), Sanger Sequencing

What Trends Are Shaping The Neurogenetic Testing Market Structure?

Leading companies in the neurofibromatosis type 1 (NF1) market are concentrating on introducing innovative products like kinase inhibitors to improve targeted treatment and patient outcomes. A kinase inhibitor is a drug type that obstructs the action of kinases, which are enzymes responsible for transferring phosphate groups to proteins, thereby regulating various cellular processes. For instance, in May 2023, AstraZeneca plc, a UK-based pharmaceutical industry company, obtained approval from China for Koselugo (selumetinib), intended for treating symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged three years and above who have neurofibromatosis type 1 (NF1). This approval expands the availability of specific treatment options for pediatric NF1 patients, improving disease management and enhancing their quality of life. The introduction of Koselugo (selumetinib) in China aligns with the growing focus on precision medicine, offering a non-surgical alternative for managing inoperable plexiform neurofibromas.

Which Companies Are Engaged In The Neurogenetic Testing Market Environment?

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children’s, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

Access The Complete Neurogenetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/neurogenetic-testing-global-market-report

Which Geographic Region Represents The Largest Neurogenetic Testing Market Share?

North America was the largest region in the neurogenetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurogenetic Testing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=16131&type=smp

Browse Through More Reports Similar to the Global Neurogenetic Testing Market 2026, By The Business Research Company

Idiopathic Pulmonary Fibrosis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Rare Neurological Disease Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Acoustic Neuroma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acoustic-neuroma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795